Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Nightingale's tests added to health assessments offered by British The Private GP Group

HEALTHAnalyst Comment23.10.2026, 07.56
Antti SiltanenAnalyst
Discuss

Summary

  • Nightingale Health has signed an agreement with The Private GP Group in the UK to include its blood analysis in the group's annual health assessments.
  • The tests will be offered in Surrey and South London, assessing 10-year risks for five common chronic diseases.
  • The integration of Nightingale's test into standard care pathways is seen as a core value creation and competitive advantage for the company.
  • While the agreement's immediate volume impact is limited, it could serve as a reference for attracting larger clients in the UK.

This content is generated by AI. You can give feedback on it in the Inderes forum.

Translation: Original published in Finnish on 10/23/2026 at 8:15 am EEST.

Nightingale Health announced on Thursday that it had signed an agreement with the British general practice, The Private GP Group. As part of the agreement, Nightingale's blood analysis will be incorporated into the group's annual health assessments. The news is a continuation of several smaller agreements announced recently. While the value of each individual agreement is likely small, together, they provide good support for our growth estimates.

Going forward, The Private GP Group will offer the test to its patients in the areas its clinics serve in Surrey and South London. The group's health assessments already include a blood test, from which Nightingale determines the 10-year risks for five common chronic diseases. In our view, the model in which Nightingale's test is integrated directly into standard sampling and the existing care pathway is at the core of the company's value creation and competitive advantage. Although the volume generated by a single small chain of general practices does not yet solve the company’s long-term growth challenges, successful implementation can serve as a strong reference for winning new, larger clients in the United Kingdom. Regarding the investment story, however, our main focus remains on how the volumes of the group’s largest international partnerships scale.

Nightingale Health operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio is broad and includes platforms and services within blood analysis that are used for disease prevention purposes. In addition to the main business, service and related ancillary services are also offered. The business is operated globally with the largest presence in Europe.

Read more on company page

Key Estimate Figures08.10

202627e28e
Revenue5.512.012.0
growth-%17.2 %118.1 %-0.4 %
EBIT (adj.)-18.8-14.1-13.5
EBIT-% (adj.)-341.8 %-117.3 %-112.7 %
EPS (adj.)-0.30-0.23-0.22
Dividend0.000.000.00
Dividend %
P/E (adj.)neg.neg.neg.
EV/EBITDAneg.neg.neg.

Forum discussions

There was just a segment of a few minutes on this on the 10 o’clock news! Nightingale wasn’t mentioned by name, but it’s great if this helps...
11/11/2026, 8:17 PM
by Yariskuski
7
mtvuutiset.fi – 11 Nov 26 Työttömien terveystarkastuksiin uusi verikoe: Sairastumisriskejä arvioidaan... Työttömien terveystarkastuksissa otetaan...
11/11/2026, 9:39 AM
by Pertti
13
Inderes Nightingale Healthin sairastumisriskien tunnistus saataville Alankomaissa... Nightingale Health Oyj | Lehdistötiedote | 10.11.2026 klo...
11/10/2026, 7:03 AM
by Pertti
21
Well, well. It could be that these continuous little breadcrumbs of news are (no longer so weak) signals of an impending tsunami. And these ...
11/6/2026, 9:50 AM
by Balle Ramsted - pienehkö kasvusijoittaja nupullaan
9
Inderes Nightingale Healthin sairastumisriskien tunnistus osaksi lontoolaisen Barnes... Nightingale Health Oyj | Lehdistötiedote | 06.11.2026...
11/6/2026, 9:02 AM
by Pertti
17
NGH doesn’t have clinical validation in Europe either for all the parameters they advertise for research use. Different audiences, different...
11/6/2026, 7:53 AM
by omegaalpha
0
As I understand it, one LDT approval covers a bundle from a total set of different blood biomarkers/values, of which there are about 250 in ...
11/6/2026, 6:08 AM
by Pertti
2